1 terminated, 1 withdrawn. 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Terminated 1, Withdrawn 1 |
Follow Hepatitis C Infection: new trials by email Literature Review of Hepatitis C Infection trials Research Report on Hepatitis C Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety Study of the Aethlon Hemopurifier Affinity plasmapheresis - End Stage Renal Disease, Hepatitis C Infection | Not applicable | Terminated | Aethlon Medical Inc. | 8 | 2014-12-01 | 2017-03-14 |
| Boceprevir in End Stage Renal Disease (ESRD) P-IFN alfa 2a, P-IFN alfa 2b, Ribavirin - Hepatitis C Infection, End Stage Renal Disease | Not applicable | Withdrawn | Columbia University | 2013-05-01 | 2015-09-23 |
Hepatitis C (2) · Kidney Failure, Chronic (2)
Blood-Borne Infections (2) · Chronic Disease (2) · Communicable Diseases (2) · Digestive System Diseases (2) · Disease Attributes (2) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Flaviviridae Infections (2) · Hepatitis (2) · Hepatitis, Viral, Human (2) · Infections (2) · Kidney Diseases (2) · Liver Diseases (2) · Male Urogenital Diseases (2) · Pathologic Processes (2)
N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide (1) · Ribavirin (1) · peginterferon alfa-2a (1)
Aethlon Medical Inc. (1) · Columbia University (1)
United States (1)
Elizabeth C Verna, MD, MS (1) · Felicia B Ricks, RD CS-R LD (1) · Ronald Ralph, M. D. FASN (1)